Which lung cancer surgery cuts tumor DNA best? new trial aims to find out.

NCT ID NCT05502523

First seen Jan 29, 2026

Summary

This study compares two standard surgical techniques for removing early-stage lung cancer: tying off the pulmonary vein first versus the pulmonary artery first. Researchers want to see which method better reduces circulating tumor DNA (ctDNA) in the blood after surgery, which may be linked to lower risk of cancer spread. About 100 adults with stage I-III non-small cell lung cancer will participate, and blood samples will be taken before and after surgery to measure ctDNA levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Abington Memorial Hospital

    RECRUITING

    Abington, Pennsylvania, 19001, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Asplundh Cancer Pavilion at Jefferson Health

    RECRUITING

    Willow Grove, Pennsylvania, 19090, United States

    Contact Phone: •••-•••-••••

  • Jefferson Health Northeast

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-••••

  • Thomas Jefferson University Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pulmonary artery-first surgical technique

What this could lead to

If successful, this study could show that a specific surgical approach reduces cancer cells in the blood, potentially improving long-term survival for early-stage lung cancer patients.

What could go wrong

This is an early-stage observational study with only 100 participants, so results may not apply to all patients. The main goal is to measure tumor DNA, not directly prove better survival or cure.

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.